Bbs Bioactive Bone Substitutes Stock Short Ratio
| BONEH Stock | EUR 0.07 0 1.47% |
BBS Bioactive Bone Substitutes fundamentals help investors to digest information that contributes to BBS Bioactive's financial success or failures. It also enables traders to predict the movement of BBS Stock. The fundamental analysis module provides a way to measure BBS Bioactive's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BBS Bioactive stock.
BBS |
BBS Bioactive Bone Substitutes Company Short Ratio Analysis
BBS Bioactive's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Based on the latest financial disclosure, BBS Bioactive Bone Substitutes has a Short Ratio of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Medical Devices industry. The short ratio for all Finland stocks is 100.0% higher than that of the company.
Did you try this?
Run CEOs Directory Now
CEOs DirectoryScreen CEOs from public companies around the world |
| All Next | Launch Module |
BBS Fundamentals
| Return On Equity | -0.61 | |||
| Return On Asset | -0.15 | |||
| Operating Margin | (278.58) % | |||
| Current Valuation | 14.53 M | |||
| Shares Outstanding | 9.67 M | |||
| Shares Owned By Insiders | 45.74 % | |||
| Shares Owned By Institutions | 1.71 % | |||
| Price To Book | 2.10 X | |||
| Price To Sales | 1,123 X | |||
| Gross Profit | (56.95 K) | |||
| EBITDA | (2.34 M) | |||
| Net Income | (2.77 M) | |||
| Cash And Equivalents | 3.44 M | |||
| Cash Per Share | 0.52 X | |||
| Total Debt | 5.12 M | |||
| Debt To Equity | 0.99 % | |||
| Current Ratio | 5.04 X | |||
| Book Value Per Share | 0.58 X | |||
| Cash Flow From Operations | (2.52 M) | |||
| Earnings Per Share | (0.42) X | |||
| Number Of Employees | 21 | |||
| Beta | -0.0943 | |||
| Market Capitalization | 12.23 M | |||
| Total Asset | 10.51 M | |||
| Z Score | 1.2 | |||
| Net Asset | 10.51 M |
About BBS Bioactive Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BBS Bioactive Bone Substitutes's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BBS Bioactive using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BBS Bioactive Bone Substitutes based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in BBS Stock
BBS Bioactive financial ratios help investors to determine whether BBS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BBS with respect to the benefits of owning BBS Bioactive security.